biolution

Afatinib 

Prev Next
Previous

Human Immunodeficiency Virus

medical illustration of Tyrosinekinase domains of EGFR/HER3 inhibited by afatinib. The main driver mutation in cancer is in the RAS gene cluster where RAS acts like a oncogene. Medicaments with ingrdients like the pan ERBB-inhibitor afatinib which binds in the tyrosine kinase domain of EGFR (red) and switches proliferative signals off stopping further tumor growth.
Next medical illustration of Cancer is one of the most common cause of death. Therefore, scientist have found multiple ways in their desire to destroy cancer ultimately. Going of immune or radiation therapies to the intake of cytotoxic ingrediences like Taxol or Doxorubicin by interfering at DNA synthesis and promote further mutations.

Topoisomerase with Doxorubicin

Tyrosinekinase domains of EGFR/HER3 inhibited by afatinib. The main driver mutation in cancer is in the RAS gene cluster where RAS acts like a oncogene. Medicaments with ingrdients like the pan ERBB-inhibitor afatinib which binds in the tyrosine kinase domain of EGFR (red) and switches proliferative signals off stopping further tumor growth.

Keywords: Color, 3D, Research, Biology, Biotechnology, General Medicine, Natural Science / Nature, Oncology, Mechanism of Action (MOA), Pathology

© biolution GmbH